A Phase I/II, multi-center, open-label study of BEZ235, administered orally on a continuous daily dosing schedule in adult patients with advanced solid malignancies including patients with advanced breast cancer.
Phase of Trial: Phase I/II
Latest Information Update: 16 Feb 2017
At a glance
- Drugs Dactolisib (Primary) ; Trastuzumab
- Indications Advanced breast cancer; Solid tumours
- Focus Adverse reactions; Biomarker
- Sponsors Novartis
- 01 Jan 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 01 Oct 2012 Planned End Date changed from 1 Oct 2012 to 1 Jul 2013 as reported by ClinicalTrials.gov.
- 01 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.